Cohance Lifesciences Limited
COHANCE · General/Diversified · NSE
₹357
Current Market Price
Fair Value (DCF)
₹154
Margin of Safety
-56.9%
Updated just now
YieldIQ Score
40/100
Piotroski F-Score
5/9
Economic Moat
Narrow
Confidence
44%
ROE
14.6%
Debt/Equity
0.00
WACC
9.8%
Market Cap
₹0.14 Lakh Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
13.3%
Return on capital employed
EV / EBITDA
34.3×
Enterprise multiple
Debt / EBITDA
1.0×
Leverage vs earnings
Interest Coverage
31.0×
EBIT covers interest
Current Ratio
2.43×
Short-term liquidity
Asset Turnover
0.36×
Revenue per ₹ of assets
Revenue CAGR (3Y)
—
3-year revenue growth
Revenue CAGR (5Y)
14.9%
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹357.05
Bear case
₹87.34
MoS -308.8%
Base case
₹153.99
MoS -131.9%
Bull case
₹211.16
MoS -69.1%
Ratio Trends
COHANCE · last 6 annual periods
ROE
14.6%
ROCE
20.4%
Operating Margin
—
Debt / Equity
0.15×
PE
—
EV / EBITDA
—
Historical Financials
COHANCE · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹1010 Cr | ₹1320 Cr | ₹369 Cr | ₹253 Cr | ₹1172 Cr | +3.8% |
| EBITDA | — | ₹713 Cr | ₹621 Cr | ₹467 Cr | ₹433 Cr | -11.7% |
| EBIT | ₹423 Cr | ₹633 Cr | ₹169 Cr | ₹73.2 Cr | — | -35.5% |
| PAT | ₹362 Cr | ₹454 Cr | ₹124 Cr | ₹53.4 Cr | ₹268 Cr | -7.3% |
| EPS (diluted) | ₹14.23 | ₹17.83 | ₹4.87 | ₹2.10 | — | -38.0% |
| CFO | ₹383 Cr | ₹330 Cr | ₹451 Cr | ₹358 Cr | ₹288 Cr | -6.9% |
| CapEx | — | — | — | — | ₹-156 Cr | — |
| FCF | — | — | — | — | ₹132 Cr | +0.0% |
| Total Assets | — | ₹1830 Cr | ₹1966 Cr | ₹2254 Cr | ₹3032 Cr | +13.5% |
| Total Debt | — | — | ₹64.6 Cr | ₹38.6 Cr | ₹279 Cr | +44.2% |
| Shareholders' Equity | — | — | ₹1735 Cr | ₹2051 Cr | ₹1841 Cr | +1.5% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
COHANCE vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
| JUBLPHARMA JUBLPHARMA | — | — | Pending | 13.5% | — |
| APLLTD Alembic Pharmaceuticals Limited | +23.3% | 52 | Undervalued | 11.2% | — |
| CAPLIPOINT CAPLIPOINT | — | — | Pending | 18.6% | — |
| ALIVUS ALIVUS | — | — | Pending | 17.2% | — |
| GRANULES Granules India Limited | +2.0% | 51 | Fairly valued | 13.5% | — |
Click a ticker to view its fair-value analysis.
Dividend History
No dividend events recorded for COHANCE in the last 10 years.
AI Analysis Summary
Model-generated description of metrics. Not investment advice. Cohance Lifesciences Limited (COHANCE.NS) trades at 357.05 vs a model fair value of 153.99, a gap of -56.9%. Piotroski F-score: 5/9. Moat...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of COHANCE →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for COHANCE →
Compare
Head-to-head with peers
Compare COHANCE side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse COHANCENow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.